182 related articles for article (PubMed ID: 38275886)
1. The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers.
Kazandjian S; Rousselle E; Dankner M; Cescon DW; Spreafico A; Ma K; Kavan P; Batist G; Rose AAN
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275886
[TBL] [Abstract][Full Text] [Related]
2. Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.
Negrao MV; Raymond VM; Lanman RB; Robichaux JP; He J; Nilsson MB; Ng PKS; Amador BE; Roarty EB; Nagy RJ; Banks KC; Zhu VW; Ng C; Chae YK; Clarke JM; Crawford JA; Meric-Bernstam F; Ignatius Ou SH; Gandara DR; Heymach JV; Bivona TG; McCoach CE
J Thorac Oncol; 2020 Oct; 15(10):1611-1623. PubMed ID: 32540409
[TBL] [Abstract][Full Text] [Related]
3.
Jones JC; Renfro LA; Al-Shamsi HO; Schrock AB; Rankin A; Zhang BY; Kasi PM; Voss JS; Leal AD; Sun J; Ross J; Ali SM; Hubbard JM; Kipp BR; McWilliams RR; Kopetz S; Wolff RA; Grothey A
J Clin Oncol; 2017 Aug; 35(23):2624-2630. PubMed ID: 28486044
[TBL] [Abstract][Full Text] [Related]
4. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
[TBL] [Abstract][Full Text] [Related]
5. Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.
Zhao Y; Yu H; Ida CM; Halling KC; Kipp BR; Geiersbach K; Rumilla KM; Gupta S; Lin MT; Zheng G
JAMA Netw Open; 2021 Jan; 4(1):e2035479. PubMed ID: 33507258
[TBL] [Abstract][Full Text] [Related]
6. Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring
Di Federico A; De Giglio A; Gelsomino F; De Biase D; Giunchi F; Palladini A; Sperandi F; Melotti B; Ardizzoni A
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884534
[TBL] [Abstract][Full Text] [Related]
7. BRAF Non-V600 Mutations in Metastatic Colorectal Cancer.
Liu J; Xie H
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760573
[TBL] [Abstract][Full Text] [Related]
8. Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.
Dankner M; Wang Y; Fazelzad R; Johnson B; Nebhan CA; Dagogo-Jack I; Myall NJ; Richtig G; Bracht JWP; Gerlinger M; Shinozaki E; Yoshino T; Kotani D; Fangusaro JR; Gautschi O; Mazieres J; Sosman JA; Kopetz S; Subbiah V; Davies MA; Groover AL; Sullivan RJ; Flaherty KT; Johnson DB; Benedetti A; Cescon DW; Spreafico A; Zogopoulos G; Rose AAN
JCO Precis Oncol; 2022 Aug; 6():e2200107. PubMed ID: 35977349
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
[TBL] [Abstract][Full Text] [Related]
10. The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients.
Lin Q; Zhang H; Ding H; Qian J; Lizaso A; Lin J; Han-Zhang H; Xiang J; Li Y; Zhu H
J Transl Med; 2019 Aug; 17(1):298. PubMed ID: 31470866
[TBL] [Abstract][Full Text] [Related]
11. Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.
Yaeger R; Kotani D; Mondaca S; Parikh AR; Bando H; Van Seventer EE; Taniguchi H; Zhao H; Thant CN; de Stanchina E; Rosen N; Corcoran RB; Yoshino T; Yao Z; Ebi H
Clin Cancer Res; 2019 Dec; 25(23):7089-7097. PubMed ID: 31515458
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapy for Melanomas Without BRAF V600 Mutations.
Menzer C; Hassel JC
Curr Treat Options Oncol; 2022 Jun; 23(6):831-842. PubMed ID: 35380338
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
14. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapy in Advanced Melanoma With Rare
Menzer C; Menzies AM; Carlino MS; Reijers I; Groen EJ; Eigentler T; de Groot JWB; van der Veldt AAM; Johnson DB; Meiss F; Schlaak M; Schilling B; Westgeest HM; Gutzmer R; Pföhler C; Meier F; Zimmer L; Suijkerbuijk KPM; Haalck T; Thoms KM; Herbschleb K; Leichsenring J; Menzer A; Kopp-Schneider A; Long GV; Kefford R; Enk A; Blank CU; Hassel JC
J Clin Oncol; 2019 Nov; 37(33):3142-3151. PubMed ID: 31580757
[TBL] [Abstract][Full Text] [Related]
16. Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.
Boussemart L; Nelson A; Wong M; Ross JS; Sosman J; Mehnert J; Daniels G; Kendra K; Ali SM; Miller VA; Schrock AB
Oncologist; 2019 May; 24(5):657-663. PubMed ID: 30683711
[TBL] [Abstract][Full Text] [Related]
17. Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights.
Dienstmann R; Elez E; Argiles G; Matos I; Sanz-Garcia E; Ortiz C; Macarulla T; Capdevila J; Alsina M; Sauri T; Verdaguer H; Vilaro M; Ruiz-Pace F; Viaplana C; Garcia A; Landolfi S; Palmer HG; Nuciforo P; Rodon J; Vivancos A; Tabernero J
Mol Oncol; 2017 Sep; 11(9):1263-1272. PubMed ID: 28618197
[TBL] [Abstract][Full Text] [Related]
18. Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.
Rajkumar S; Berry D; Heney KA; Strong C; Ramsay L; Lajoie M; Alkallas R; Nguyen TT; Thomson C; Ahanfeshar-Adams M; Dankner M; Petrella T; Rose AAN; Siegel PM; Watson IR
Cell Rep; 2022 Apr; 39(1):110634. PubMed ID: 35385748
[TBL] [Abstract][Full Text] [Related]
19. Encorafenib plus binimetinib in patients with
Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE
Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology.
Dankner M
JCO Precis Oncol; 2018 Nov; 2():1-12. PubMed ID: 35135170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]